The stock of Acrivon Therapeutics Inc (NASDAQ: ACRV) has increased by 13.36 when compared to last closing price of 8.46.Despite this, the company has seen a gain of 13.36% in its stock price over the last five trading days. Market Watch reported 2024-04-24 that Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
Is It Worth Investing in Acrivon Therapeutics Inc (NASDAQ: ACRV) Right Now?
The stock has a 36-month beta value of 1.27. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACRV is 20.70M, and at present, short sellers hold a 4.95% of that float. On May 06, 2024, the average trading volume of ACRV was 783.66K shares.
ACRV’s Market Performance
The stock of Acrivon Therapeutics Inc (ACRV) has seen a 13.36% increase in the past week, with a 43.35% rise in the past month, and a 151.05% gain in the past quarter. The volatility ratio for the week is 16.84%, and the volatility levels for the past 30 days are at 15.15% for ACRV. The simple moving average for the past 20 days is 5.06% for ACRV’s stock, with a 35.15% simple moving average for the past 200 days.
Analysts’ Opinion of ACRV
JMP Securities, on the other hand, stated in their research note that they expect to see ACRV reach a price target of $14. The rating they have provided for ACRV stocks is “Mkt Outperform” according to the report published on March 01st, 2024.
Jefferies gave a rating of “Buy” to ACRV, setting the target price at $12 in the report published on December 15th of the previous year.
ACRV Trading at 37.20% from the 50-Day Moving Average
After a stumble in the market that brought ACRV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.94% of loss for the given period.
Volatility was left at 15.15%, however, over the last 30 days, the volatility rate increased by 16.84%, as shares surge +47.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +151.05% upper at present.
During the last 5 trading sessions, ACRV rose by +13.36%, which changed the moving average for the period of 200-days by -27.18% in comparison to the 20-day moving average, which settled at $9.28. In addition, Acrivon Therapeutics Inc saw 94.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRV starting from PERCEPTIVE ADVISORS LLC, who purchase 2,353,000 shares at the price of $8.50 back on Apr 11 ’24. After this action, PERCEPTIVE ADVISORS LLC now owns 5,360,858 shares of Acrivon Therapeutics Inc, valued at $20,000,500 using the latest closing price.
Chione Ltd, the 10% Owner of Acrivon Therapeutics Inc, sale 16 shares at $12.93 during a trade that took place back on Jun 26 ’23, which means that Chione Ltd is holding 3,848,632 shares at $207 based on the most recent closing price.
Stock Fundamentals for ACRV
The total capital return value is set at -0.54. Equity return is now at value -41.41, with -37.80 for asset returns.
Based on Acrivon Therapeutics Inc (ACRV), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -9.18. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 40.99.
Currently, EBITDA for the company is -66.7 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.75.
Conclusion
To sum up, Acrivon Therapeutics Inc (ACRV) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
